Cerus Corp (CERS) 4.79 $CERS
Trade-Ideas: Cerus (CERS) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Apr 24, 9:05AM CDT
Trade-Ideas LLC identified Cerus (CERS) as a strong on high relative volume candidate
CERS: 4.79 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 11:45AM CDT
CERS: 4.79 (+0.20), HBP: 3.84 (-0.10), CIDM: 0.95 (-0.02), HNI: 51.98 (+0.71), MDSO: 57.59 (+0.05), HZO: 22.88 (-1.52), NKA: 2.06 (+0.06), NVGN: 6.54 (-0.01), EGT: 2.18 (-0.02), VLTC: 11.54 (+0.50), ADPT: 63.78 (+2.13), CALI: 2.28 (-0.05), XXII: 1.35 (-0.05), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), SIFY: 1.46 (-0.14), SCYX: 9.47 (-0.52), CLFD: 14.25 (+0.04), VGGL: 2.55 (-0.10), MOBL: 6.97 (-0.14)
Hot Stock: Cerus, Shares Gain 10.9% (CERS)
Comtex SmarTrend(R) - Thu Apr 23, 10:49AM CDT
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 10.9% to $4.55 on 1.3x average daily volume. Thus far today, Cerus has traded 1.4 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's -0.0%) and outperformed the S&P 500 (10.9% to the S&P's 0.0%) during today's trading.
CERS: 4.79 (+0.20)
First Week of CERS June 19th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:12AM CDT
Investors in Cerus Corp. saw new options become available this week, for the June 19th expiration.
CERS: 4.79 (+0.20)
Cerus to Release First Quarter 2015 Results on May 5, 2015
Business Wire - Wed Apr 22, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 5, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.79 (+0.20)
Apheresis Equipment - 2015 Global Strategic Business Report: Rising Cancer Incidence to Drive Volume of Apheresis Procedures
M2 - Thu Apr 16, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sjpfd/apheresis) has announced the addition of the "Apheresis Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Apheresis Equipment in US$ Thousands by the following Types: Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global market is analyzed by the following Applications: Erythrocytapheresis, Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 14 companies including many key and niche players such as: - Asahi Kasei Medical Co., Ltd. (Japan) - B Braun Melsungen AG (Germany) - Cerus Corporation (US) - Fresenius Kabi (Germany) - Fenwal, Inc. (US) - Haemonetics Corporation (US) - HemaCare Corp. (US) - Kaneka Corporation (Japan) - Kawasumi Laboratories, Inc. (Japan) - Medica SpA (Italy) - NIKKISO Europe GmbH (Germany) - Terumo BCT, Inc. (US) - Therakos, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. KEY MARKET TRENDS & DRIVERS 3. TECHNOLOGY OVERVIEW 4. BLOOD COMPONENTS & DERIVATIVES 5. PRODUCT DEVELOPMENTS/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 14 (including Divisions/Subsidiaries - 21) - The United States (9) - Japan (3) - Europe (9) - - Germany (6) - - Italy (3) For more information visit http://www.researchandmarkets.com/research/8sjpfd/apheresis
CERS: 4.79 (+0.20), HAE: 43.35 (+0.74)
First patient enrolled in study of Cerus Intercept Blood System for tropical mosquito-borne diseases
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 12:55PM CDT
CERS: 4.79 (+0.20)
First Patient Enrolled in Cerus' TRUE Study With the American Red Cross to Address Chikungunya and Dengue Blood Safety Risks With Pathogen Reduced Platelets
Business Wire - Mon Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets available to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE). The American Red Cross is producing INTERCEPT platelet components for the study, which is being conducted in Puerto Rico.
CERS: 4.79 (+0.20)
Cerus Squeezes Healthy Blood From A Stone
ARK Investment Management - Seeking Alpha - Sat Feb 28, 8:27AM CST
By James Bannon, Analyst: Genomics Blood transfusions are extremely common. One in every seven people entering a hospital will need a blood transfusion, and so will 18% of the millions of cancer patients globally. In total, roughly 15 million...
CERS: 4.79 (+0.20)
RSI Alert: Cerus Corp. Now Oversold
MarketNewsVideo.com - Fri Feb 27, 11:02AM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
CERS: 4.79 (+0.20)
Cerus' (CERS) CEO William Greenman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 7:10PM CST
CERS: 4.79 (+0.20)
Cerus reports 4Q loss
Automated Insights - Thu Feb 26, 4:58PM CST
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Thursday reported a loss of $20 million in its fourth quarter.
CERS: 4.79 (+0.20)
Cerus (CERS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 26, 3:10PM CST
CERS: 4.79 (+0.20)
Cerus EPS of -$0.25
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:05PM CST
CERS: 4.79 (+0.20)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 4:35PM CST
HLF: 41.10 (-3.75), MNST: 141.78 (+1.42), NOG: 8.38 (-0.14), MAIN: 31.39 (+0.09), MVNR: 17.44 (-0.05), EVHC: 39.58 (+0.05), RP: 19.76 (+0.24), ENV: 54.31 (-0.22), BCEI: 24.79 (-0.22), CLNE: 8.07 (+0.42), MITT: 19.49 (+0.13), KBR: 15.85 (-0.23), NVAX: 8.58 (-0.07), PKT: 11.43 (-0.02), KND: 24.42 (+0.02), CSU: 26.68 (+0.11), OLED: 47.60 (+0.26), IM: 25.65 (+0.08), DGI: 33.16 (-0.63), AHT: 9.52 (+0.02), LYV: 25.99 (+0.01), ECOL: 49.43 (+0.31), PEGA: 22.35 (+0.13), PODD: 30.72 (+0.11), CROX: 12.97 (unch), AVD: 10.89 (-0.35), AL: 38.75 (-0.32), RBA: 25.27 (+0.25), ADSK: 62.64 (-0.11), ECPG: 41.70 (-0.08), AIRM: 47.62 (-0.31), ARUN: 24.61 (-0.03), ENOC: 11.39 (+0.12), AEGR: 25.42 (-0.52), MDRX: 12.59 (-0.15), RMTI: 10.37 (-0.23), HPTX: 45.97 (-0.11), PSIX: 64.10 (-0.19), ABTL: 15.72 (+0.35), PFMT: 3.22 (-0.04), R: 98.84 (-0.74), CERS: 4.79 (+0.20), EVC: 6.80 (+0.01), IMMR: 10.03 (-0.15), CUBE: 23.79 (+0.09), BLOX: 24.52 (+0.23), OUT: 29.21 (+0.04), OVTI: 26.62 (-0.19), MTZ: 17.88 (+0.13), APEI: 30.58 (-0.33), MENT: 24.68 (-0.40), BIO: 137.41 (+0.01), JCP: 8.41 (-0.07), PE: 16.72 (+0.02), NMBL: 24.38 (-0.28), GPS: 40.86 (-0.36), ROST: 104.38 (-0.13)
Cerus to Release Fourth Quarter 2014 Results on February 26, 2015
Business Wire - Fri Feb 13, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter results will be released on Thursday, February 26, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.79 (+0.20)
Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Thu Feb 05, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the SunCoast Blood Bank (SCBB) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. SCBB collects over 45,000 units of blood products, including 6,000 units of platelets and over 5,500 plasma units per year, to support 12 hospitals.
CERS: 4.79 (+0.20)
Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Wed Feb 04, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the Blood Bank of Delmarva (BBD) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. BBD provides blood transfusion products and services to hospitals and patients in Delaware, Cecil County, Maryland, as well as Maryland's and Virginia's Eastern Shores. BBD supplies approximately 13,000 platelet and 21,000 plasma units per year.
CERS: 4.79 (+0.20)
Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
PR Newswire - Wed Jan 28, 7:00AM CST
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved ASI's manufacturing facility in Riverview, Michigan for the manufacture of Amotosalen, the API in Cerus Corporation's (NASDAQ: CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 4.79 (+0.20)
Trade-Ideas: Cerus (CERS) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Apr 24, 9:05AM CDT
Trade-Ideas LLC identified Cerus (CERS) as a strong on high relative volume candidate
CERS: 4.79 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 11:45AM CDT
CERS: 4.79 (+0.20), HBP: 3.84 (-0.10), CIDM: 0.95 (-0.02), HNI: 51.98 (+0.71), MDSO: 57.59 (+0.05), HZO: 22.88 (-1.52), NKA: 2.06 (+0.06), NVGN: 6.54 (-0.01), EGT: 2.18 (-0.02), VLTC: 11.54 (+0.50), ADPT: 63.78 (+2.13), CALI: 2.28 (-0.05), XXII: 1.35 (-0.05), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), SIFY: 1.46 (-0.14), SCYX: 9.47 (-0.52), CLFD: 14.25 (+0.04), VGGL: 2.55 (-0.10), MOBL: 6.97 (-0.14)
Hot Stock: Cerus, Shares Gain 10.9% (CERS)
Comtex SmarTrend(R) - Thu Apr 23, 10:49AM CDT
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 10.9% to $4.55 on 1.3x average daily volume. Thus far today, Cerus has traded 1.4 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's -0.0%) and outperformed the S&P 500 (10.9% to the S&P's 0.0%) during today's trading.
CERS: 4.79 (+0.20)
First Week of CERS June 19th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:12AM CDT
Investors in Cerus Corp. saw new options become available this week, for the June 19th expiration.
CERS: 4.79 (+0.20)
Cerus to Release First Quarter 2015 Results on May 5, 2015
Business Wire - Wed Apr 22, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 5, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.79 (+0.20)
Apheresis Equipment - 2015 Global Strategic Business Report: Rising Cancer Incidence to Drive Volume of Apheresis Procedures
M2 - Thu Apr 16, 4:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8sjpfd/apheresis) has announced the addition of the "Apheresis Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Apheresis Equipment in US$ Thousands by the following Types: Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global market is analyzed by the following Applications: Erythrocytapheresis, Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 14 companies including many key and niche players such as: - Asahi Kasei Medical Co., Ltd. (Japan) - B Braun Melsungen AG (Germany) - Cerus Corporation (US) - Fresenius Kabi (Germany) - Fenwal, Inc. (US) - Haemonetics Corporation (US) - HemaCare Corp. (US) - Kaneka Corporation (Japan) - Kawasumi Laboratories, Inc. (Japan) - Medica SpA (Italy) - NIKKISO Europe GmbH (Germany) - Terumo BCT, Inc. (US) - Therakos, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. KEY MARKET TRENDS & DRIVERS 3. TECHNOLOGY OVERVIEW 4. BLOOD COMPONENTS & DERIVATIVES 5. PRODUCT DEVELOPMENTS/APPROVALS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 14 (including Divisions/Subsidiaries - 21) - The United States (9) - Japan (3) - Europe (9) - - Germany (6) - - Italy (3) For more information visit http://www.researchandmarkets.com/research/8sjpfd/apheresis
CERS: 4.79 (+0.20), HAE: 43.35 (+0.74)
First patient enrolled in study of Cerus Intercept Blood System for tropical mosquito-borne diseases
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 12:55PM CDT
CERS: 4.79 (+0.20)
First Patient Enrolled in Cerus' TRUE Study With the American Red Cross to Address Chikungunya and Dengue Blood Safety Risks With Pathogen Reduced Platelets
Business Wire - Mon Mar 16, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets available to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE). The American Red Cross is producing INTERCEPT platelet components for the study, which is being conducted in Puerto Rico.
CERS: 4.79 (+0.20)
Cerus Squeezes Healthy Blood From A Stone
ARK Investment Management - Seeking Alpha - Sat Feb 28, 8:27AM CST
By James Bannon, Analyst: Genomics Blood transfusions are extremely common. One in every seven people entering a hospital will need a blood transfusion, and so will 18% of the millions of cancer patients globally. In total, roughly 15 million...
CERS: 4.79 (+0.20)
RSI Alert: Cerus Corp. Now Oversold
MarketNewsVideo.com - Fri Feb 27, 11:02AM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
CERS: 4.79 (+0.20)
Cerus' (CERS) CEO William Greenman on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 7:10PM CST
CERS: 4.79 (+0.20)
Cerus reports 4Q loss
Automated Insights - Thu Feb 26, 4:58PM CST
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Thursday reported a loss of $20 million in its fourth quarter.
CERS: 4.79 (+0.20)
Cerus (CERS) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 26, 3:10PM CST
CERS: 4.79 (+0.20)
Cerus EPS of -$0.25
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 3:05PM CST
CERS: 4.79 (+0.20)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 4:35PM CST
HLF: 41.10 (-3.75), MNST: 141.78 (+1.42), NOG: 8.38 (-0.14), MAIN: 31.39 (+0.09), MVNR: 17.44 (-0.05), EVHC: 39.58 (+0.05), RP: 19.76 (+0.24), ENV: 54.31 (-0.22), BCEI: 24.79 (-0.22), CLNE: 8.07 (+0.42), MITT: 19.49 (+0.13), KBR: 15.85 (-0.23), NVAX: 8.58 (-0.07), PKT: 11.43 (-0.02), KND: 24.42 (+0.02), CSU: 26.68 (+0.11), OLED: 47.60 (+0.26), IM: 25.65 (+0.08), DGI: 33.16 (-0.63), AHT: 9.52 (+0.02), LYV: 25.99 (+0.01), ECOL: 49.43 (+0.31), PEGA: 22.35 (+0.13), PODD: 30.72 (+0.11), CROX: 12.97 (unch), AVD: 10.89 (-0.35), AL: 38.75 (-0.32), RBA: 25.27 (+0.25), ADSK: 62.64 (-0.11), ECPG: 41.70 (-0.08), AIRM: 47.62 (-0.31), ARUN: 24.61 (-0.03), ENOC: 11.39 (+0.12), AEGR: 25.42 (-0.52), MDRX: 12.59 (-0.15), RMTI: 10.37 (-0.23), HPTX: 45.97 (-0.11), PSIX: 64.10 (-0.19), ABTL: 15.72 (+0.35), PFMT: 3.22 (-0.04), R: 98.84 (-0.74), CERS: 4.79 (+0.20), EVC: 6.80 (+0.01), IMMR: 10.03 (-0.15), CUBE: 23.79 (+0.09), BLOX: 24.52 (+0.23), OUT: 29.21 (+0.04), OVTI: 26.62 (-0.19), MTZ: 17.88 (+0.13), APEI: 30.58 (-0.33), MENT: 24.68 (-0.40), BIO: 137.41 (+0.01), JCP: 8.41 (-0.07), PE: 16.72 (+0.02), NMBL: 24.38 (-0.28), GPS: 40.86 (-0.36), ROST: 104.38 (-0.13)
Cerus to Release Fourth Quarter 2014 Results on February 26, 2015
Business Wire - Fri Feb 13, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter results will be released on Thursday, February 26, 2015, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 4.79 (+0.20)
Cerus and SunCoast Blood Bank Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Thu Feb 05, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the SunCoast Blood Bank (SCBB) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. SCBB collects over 45,000 units of blood products, including 6,000 units of platelets and over 5,500 plasma units per year, to support 12 hospitals.
CERS: 4.79 (+0.20)
Cerus and Blood Bank of Delmarva Enter into Agreement for the Use of INTERCEPT Platelets and Plasma
Business Wire - Wed Feb 04, 7:31AM CST
Cerus Corporation (NASDAQ: CERS) and the Blood Bank of Delmarva (BBD) announced today that they have signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. BBD provides blood transfusion products and services to hospitals and patients in Delaware, Cecil County, Maryland, as well as Maryland's and Virginia's Eastern Shores. BBD supplies approximately 13,000 platelet and 21,000 plasma units per year.
CERS: 4.79 (+0.20)
Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
PR Newswire - Wed Jan 28, 7:00AM CST
Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, is pleased to announce the U.S Food and Drug Administration (FDA) has approved ASI's manufacturing facility in Riverview, Michigan for the manufacture of Amotosalen, the API in Cerus Corporation's (NASDAQ: CERS) INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogen-reduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 4.79 (+0.20)
